Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) — Working Capital to Net Assets Ratio
Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) has a Working Capital to Net Assets ratio of 45.7% as of September 2025. Working capital of CN¥524.65 Million (current assets of CN¥1.06 Billion minus current liabilities of CN¥530.88 Million) is measured against net assets of CN¥1.15 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shaanxi Meibang Pharmaceutical Group Co (605033) financial flexibility to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shaanxi Meibang Pharmaceutical Group Co Ltd Working Capital to Net Assets (2017–2024)
This chart shows how Shaanxi Meibang Pharmaceutical Group Co Ltd's Working Capital to Net Assets ratio has evolved across 8 annual periods from 2017 to 2024. As of September 2025, the ratio stands at 45.7%, reflecting working capital of CN¥524.65 Million against net assets of CN¥1.15 Billion CNY. See 605033 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shaanxi Meibang Pharmaceutical Group Co Ltd from 2017 to 2024, covering 8 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 605033 market cap overview.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 42.7% | CN¥480.45 Million | CN¥1.12 Billion | CN¥1.10 Billion | CN¥616.26 Million | ▼ -12.1 pp |
| 2023 | 54.8% | CN¥610.89 Million | CN¥1.11 Billion | CN¥1.07 Billion | CN¥460.91 Million | ▼ -20.5 pp |
| 2022 | 75.4% | CN¥818.69 Million | CN¥1.09 Billion | CN¥1.19 Billion | CN¥369.72 Million | ▼ -2.8 pp |
| 2021 | 78.2% | CN¥755.71 Million | CN¥966.95 Million | CN¥1.19 Billion | CN¥437.07 Million | ▲ +12.4 pp |
| 2020 | 65.7% | CN¥295.43 Million | CN¥449.37 Million | CN¥606.16 Million | CN¥310.73 Million | ▼ -4.6 pp |
| 2019 | 70.4% | CN¥260.87 Million | CN¥370.63 Million | CN¥536.45 Million | CN¥275.58 Million | ▲ +2.9 pp |
| 2018 | 67.5% | CN¥186.52 Million | CN¥276.37 Million | CN¥478.37 Million | CN¥291.85 Million | ▲ +8.4 pp |
| 2017 | 59.1% | CN¥106.58 Million | CN¥180.43 Million | CN¥426.47 Million | CN¥319.90 Million | — |